Phase III Keynote-789 Trial of Platinum + Pemetrexed +/- Pembrolizumab in EGFR + NSCLC

•  492 patients
•  no Progression-free survival (5.6 v 5.5m) or Oculus Sinister (15.9 v 14.7m) benefit with Immune checkpoint inhibitors
•  Treatment-Related Adverse Events  (43.7% with Immune checkpoint inhibitors, 38.6% without)

Not a beneficial strategy in this disease.

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR–Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer

Authors: James Chih-Hsin Yang, Dae Ho Lee, Jong-Seok Lee,  Yun Fan,  Filippo de Marinis,  Eiji Iwama, Takako Inoue,  Jerónimo Rodríguez-Cid, Li Zhang,  Cheng-Ta Yang, Emmanuel de la Mora Jimenez,  Jianying Zhou,  Maurice Pérol,  Ki Hyeong Lee,  David Vicente, Eiki Ichihara,  Gregory J. Riely,  Yiwen Luo,  Diana Chirovsky,  M. Catherine Pietanza,  Niyati Bhagwati,  and Shun Lu.”

Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), Professor in RCSI and Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded and cooperative group clinical trials.

She has received a number of grants including a young investigator award from the International Association for the Study of Lung Cancer (IASLC), Lung Cancer Foundation of America (LCFA), and a career development award from the National Institutes of Health (NIH) KL2-program. She is the IASLC Communications Committee Chair.